New Two-Pronged attack on tough breast cancer shows promise
NCT ID NCT07394387
Summary
This study is testing a new strategy for treating early-stage triple-negative breast cancer, an aggressive type with fewer treatment options. Researchers want to see if using a focused ultrasound (HIFU) to destroy the tumor and an immunotherapy drug (PD-1 inhibitor) to activate the body's defenses *before* starting standard chemotherapy makes the overall treatment more effective. The main goal is to see if this approach can completely eliminate the cancer before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.